Literature DB >> 12234866

Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.

Ryan Reinke1, Deborah J Lee, W Edward Robinson.   

Abstract

L-731,988 inhibits human immunodeficiency virus (HIV) replication through integrase. In this study, approximately 600 nM L-731,988 inhibited the replication of 12 HIV type 1 isolates from multiple clades, including primary isolates and cloned viruses. These data suggest that diketo acids or their derivatives may prove useful on a worldwide basis in treating HIV infection.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12234866      PMCID： PMC128787          DOI： 10.1128/AAC.46.10.3301-3303.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.

Authors:  S A Wegner; S K Brodine; J R Mascola; S A Tasker; R A Shaffer; M J Starkey; A Barile; G J Martin; N Aronson; W W Emmons; K Stephan; S Bloor; J Vingerhoets; K Hertogs; B Larder
Journal:  AIDS       Date:  2000-05-26       Impact factor: 4.177

2.  Natural selection results in conservation of HIV-1 integrase activity despite sequence variability.

Authors:  R Reinke; N R Steffen; W E Robinson
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

3.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

4.  Inhibitors of HIV-1 replication [corrected; erratum to be published] that inhibit HIV integrase.

Authors:  W E Robinson; M G Reinecke; S Abdel-Malek; Q Jia; S A Chow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

5.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.

Authors:  D J Hazuda; P Felock; M Witmer; A Wolfe; K Stillmock; J A Grobler; A Espeseth; L Gabryelski; W Schleif; C Blau; M D Miller
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

6.  Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release.

Authors:  W E Robinson; D C Montefiori; D H Gillespie; W M Mitchell
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

7.  Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase.

Authors:  W E Robinson; M Cordeiro; S Abdel-Malek; Q Jia; S A Chow; M G Reinecke; W M Mitchell
Journal:  Mol Pharmacol       Date:  1996-10       Impact factor: 4.436

8.  Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids.

Authors:  K Zhu; M L Cordeiro; J Atienza; W E Robinson; S A Chow
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

9.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

Authors:  L G Gürtler; P H Hauser; J Eberle; A von Brunn; S Knapp; L Zekeng; J M Tsague; L Kaptue
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay.

Authors:  D C Montefiori; W E Robinson; S S Schuffman; W M Mitchell
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948
View more
  8 in total

Review 1.  Dolutegravir: clinical efficacy and role in HIV therapy.

Authors:  Alessandra Fantauzzi; Ivano Mezzaroma
Journal:  Ther Adv Chronic Dis       Date:  2014-07       Impact factor: 5.091

2.  HIV Drug Resistance and the Advent of Integrase Inhibitors.

Authors:  Peter K Quashie; Thibault Mesplède; Mark A Wainberg
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

3.  Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.

Authors:  Deborah J Lee; W E Robinson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

4.  Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137).

Authors:  Kazuya Shimura; Eiichi Kodama; Yasuko Sakagami; Yuji Matsuzaki; Wataru Watanabe; Kazunobu Yamataka; Yasuo Watanabe; Yoshitsugu Ohata; Satoki Doi; Motohide Sato; Mitsuki Kano; Satoru Ikeda; Masao Matsuoka
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

5.  Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.

Authors:  Olivia Goethals; Reginald Clayton; Marcia Van Ginderen; Inge Vereycken; Elisabeth Wagemans; Peggy Geluykens; Koen Dockx; Rudy Strijbos; Veerle Smits; Ann Vos; Geert Meersseman; Dirk Jochmans; Kurt Vermeire; Dominique Schols; Sabine Hallenberger; Kurt Hertogs
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

6.  Potential benefit of dolutegravir once daily: efficacy and safety.

Authors:  Alessandra Fantauzzi; Ombretta Turriziani; Ivano Mezzaroma
Journal:  HIV AIDS (Auckl)       Date:  2013-02-07

Review 7.  Novel therapeutic strategies targeting HIV integrase.

Authors:  Peter K Quashie; Richard D Sloan; Mark A Wainberg
Journal:  BMC Med       Date:  2012-04-12       Impact factor: 8.775

Review 8.  The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Authors:  Mark A Wainberg
Journal:  Scientifica (Cairo)       Date:  2012-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.